23.09.19: Not intended for U.S. and UK Media

Vitrakvi® (larotrectinib) receives first tumor-agnostic approval in EUPrecision oncology treatment Vitrakvi® (larotrectinib) approved for the treatment of adults and children with locally advanced or metastatic solid tumors that have a rare genomic alteration called an NTRK gene fusion / Vitrakvi, which was exclusively designed to treat TRK fusion cancer, is the first therapy in the EU with a tumor-agnostic indication / Larotrectinib provides high response rates and durable responses in adults and children with TRK fusion cancer, including primary CNS tumors and brain metastases / In studies, larotrectinib demonstrated an overall response rate of 72% including 16% complete responses, with 75% of patients still on treatment after one year / Larotrectinib showed a favorable safety profile, with the majority of adverse events (AEs) being grade 1 or 2; only 3% of patients had to stop therapy due to treatment-emergent AEsmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news